Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABL503 |
Synonyms | |
Therapy Description |
ABL503 is a bispecific antibody that targets both CD274 (PD-L1) and TNFRSF9 (4-1BB), leading to activation of TNFRSF9 (4-1BB) and decreased CD274 (PD-L1) signaling, potentially resulting in activation of an antitumor immune response and inhibition of tumor growth (PMID: 34230109). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABL503 | ABL-503|ABL 503 | PD-L1/PD-1 antibody 117 TNFRSF9 Antibody 30 | ABL503 is a bispecific antibody that targets both CD274 (PD-L1) and TNFRSF9 (4-1BB), leading to activation of TNFRSF9 (4-1BB) and decreased CD274 (PD-L1) signaling, potentially resulting in activation of an antitumor immune response and inhibition of tumor growth (PMID: 34230109). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04762641 | Phase I | ABL503 | This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |